These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9638 related articles for article (PubMed ID: 14567031)
1. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Rossi CR; Mocellin S; Pilati P; Foletto M; Quintieri L; Palatini P; Lise M Surg Oncol Clin N Am; 2003 Jul; 12(3):781-94. PubMed ID: 14567031 [TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234 [TBL] [Abstract][Full Text] [Related]
3. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Katz MH; Barone RM Surg Oncol Clin N Am; 2003 Jul; 12(3):673-88. PubMed ID: 14567024 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intraperitoneal mitomycin C. van Ruth S; Verwaal VJ; Zoetmulder FA Surg Oncol Clin N Am; 2003 Jul; 12(3):771-80. PubMed ID: 14567030 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Ansaloni L; Coccolini F; Morosi L; Ballerini A; Ceresoli M; Grosso G; Bertoli P; Busci LM; Lotti M; Cambria F; Pisano M; Rossetti D; Frigerio L; D'Incalci M; Zucchetti M Br J Cancer; 2015 Jan; 112(2):306-12. PubMed ID: 25461804 [TBL] [Abstract][Full Text] [Related]
6. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537 [TBL] [Abstract][Full Text] [Related]
7. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis]. Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661 [TBL] [Abstract][Full Text] [Related]
8. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Elias DM; Sideris L Surg Oncol Clin N Am; 2003 Jul; 12(3):755-69, xiv. PubMed ID: 14567029 [TBL] [Abstract][Full Text] [Related]
10. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Sticca RP; Dach BW Surg Oncol Clin N Am; 2003 Jul; 12(3):689-701. PubMed ID: 14567025 [TBL] [Abstract][Full Text] [Related]
11. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study. Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Zeamari S; Floot B; van der Vange N; Stewart FA Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435 [TBL] [Abstract][Full Text] [Related]
13. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Chauffert B; Favoulet P; Polycarpe E; Duvillard C; Beltramo JL; Bichat F; Rat P; Genne P; Benoit L Surg Oncol Clin N Am; 2003 Jul; 12(3):835-48. PubMed ID: 14567035 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis. Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398 [TBL] [Abstract][Full Text] [Related]
16. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH Oncology; 1998; 55(2):130-8. PubMed ID: 9499187 [TBL] [Abstract][Full Text] [Related]
17. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Rossi CR; Deraco M; De Simone M; Mocellin S; Pilati P; Foletto M; Cavaliere F; Kusamura S; Gronchi A; Lise M Cancer; 2004 May; 100(9):1943-50. PubMed ID: 15112276 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy]. Costamagna D; Scuderi S; Vaira M; Barone R; De Simone M Tumori; 2003; 89(4 Suppl):40-2. PubMed ID: 12903541 [TBL] [Abstract][Full Text] [Related]
19. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up]. Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]